- Home
- IMVT
IMVT
Immunovant Inc.
as of 03-06-2026 3:54pm EST
$26.54
$0.18
-0.69%
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 5.3B | IPO Year: | 2019 |
| Target Price: | $30.78 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.04 | EPS Growth: | -45.21 |
| 52 Week Low/High: | $12.72 - $29.25 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -13.04 | Index: | N/A |
| Free Cash Flow: | -376633000.0 | FCF Growth: | N/A |
AI-Powered IMVT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 72.50%
72.50%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Immunovant Inc. (IMVT)
Gloria Melanie
Sell
Chief Operating Officer
IMVT Feb 25, 2026
Avg Cost/Share
$28.01
Shares
3,238
Total Value
$90,183.50
Owned After
170,273
Stout Jay S
Sell
Chief Technology Officer
IMVT Jan 21, 2026
Avg Cost/Share
$26.03
Shares
1,977
Total Value
$51,461.31
Owned After
197,634
SEC Form 4
Stout Jay S
Sell
Chief Technology Officer
IMVT Jan 7, 2026
Avg Cost/Share
$26.72
Shares
1,203
Total Value
$31,914.08
Owned After
197,634
Van Tuyl Christopher
Sell
Chief Legal Officer
IMVT Dec 18, 2025
Avg Cost/Share
$27.08
Shares
10,813
Total Value
$290,942.54
Owned After
149,930
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Gloria Melanie | IMVT | Chief Operating Officer | Feb 25, 2026 | Sell | $28.01 | 3,238 | $90,183.50 | 170,273 | |
| Stout Jay S | IMVT | Chief Technology Officer | Jan 21, 2026 | Sell | $26.03 | 1,977 | $51,461.31 | 197,634 | |
| Stout Jay S | IMVT | Chief Technology Officer | Jan 7, 2026 | Sell | $26.72 | 1,203 | $31,914.08 | 197,634 | |
| Van Tuyl Christopher | IMVT | Chief Legal Officer | Dec 18, 2025 | Sell | $27.08 | 10,813 | $290,942.54 | 149,930 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 6, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 6, 2026 · 100% conf.
AI Prediction BUY
1D
+3.07%
$27.88
5D
+6.33%
$28.76
20D
+9.52%
$29.63
Price: $27.05 Prob +5D: 100% AUC: 1.000
0001764013-26-000010
imvt-202602060001764013FALSE00017640132026-02-062026-02-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2026
IMMUNOVANT, INC.
(Exact name of Registrant as specified in its Charter)
Delaware001-3890683-2771572 (State or other jurisdiction of incorporation or organization) (Commission File Number)(IRS Employer Identification No.)
1000 Park Forty Plaza, Suite 210 Durham,NC27713 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (917) 410-3120
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par value per shareIMVTThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 6, 2026, Immunovant, Inc. (“the Company”) issued a press release announcing its financial results for its fiscal third quarter and nine months ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 shall not be incorporated by reference in any filing with the U.S. Securities and Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description 99.1Press release, dated February 6, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNOVANT, INC.
By: /s/ Tiago Girao Tiago Girao Chief Financial Officer Date: February 6, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 10, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 10, 2025
0001764013-25-000148
imvt-202511100001764013FALSE00017640132025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025
IMMUNOVANT, INC.
(Exact name of Registrant as specified in its Charter)
Delaware001-3890683-2771572 (State or other jurisdiction of incorporation or organization) (Commission File Number)(IRS Employer Identification No.)
320 West 37th Street New York,NY10018 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (917) 580-3099
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par value per shareIMVTThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On November 10, 2025, Immunovant, Inc., or the Company, issued a press release announcing its financial results for its fiscal second quarter and six months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 shall not be incorporated by reference in any filing with the U.S. Securities and Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description 99.1Press release, dated November 10, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNOVANT, INC.
By: /s/ Tiago Girao Tiago Girao Chief Financial Officer Date: November 10, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 11, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 11, 2025
0001764013-25-000128
imvt-202508110001764013FALSE00017640132025-08-112025-08-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025
IMMUNOVANT, INC.
(Exact name of Registrant as specified in its Charter)
Delaware001-3890683-2771572 (State or other jurisdiction of incorporation or organization) (Commission File Number)(IRS Employer Identification No.)
320 West 37th Street New York,NY10018 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (917) 580-3099
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par value per shareIMVTThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On August 11, 2025, Immunovant, Inc., or the Company, issued a press release announcing its financial results for its fiscal first quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 shall not be incorporated by reference in any filing with the U.S. Securities and Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description 99.1Press release, dated August 11, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNOVANT, INC.
By: /s/ Tiago Girao Tiago Girao Chief Financial Officer Date: August 11, 2025
Latest Immunovant Inc. News
IMVT Breaking Stock News: Dive into IMVT Ticker-Specific Updates for Smart Investing
Compare IMVT vs Leading Stocks
See how IMVT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IMVT Immunovant Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.